OPKO Health Inc.
No price chart data available for 1D timeframe.
Rating
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
OPKO Health, Inc. operates as a healthcare enterprise with a dual focus on diagnostics and pharmaceuticals. Its operations span the United States, Ireland, Chile, Spain, Israel, Mexico, and other inte...
Latest News
5 days ago · globenewswire.com
OPKO Health to Report Third Quarter 2026 Financial Results on November 4, 2026MIAMI, Oct. 28, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (OPKO) (NASDAQ: OPK), a multinational biopharmaceutical company, today announced that it will report operating and financial results for the third quarter 2026 on Wednesday, November 4, 2026. OPKO's senior management will host a conference call and webcast at 4:30 p.m. ET to provide a business update, discuss results and financial guidance.
6 days ago · globenewswire.com
OPKO Health's OPKO Biologics Doses First Participant in Phase 1/2a Trial of OPK-8801001 for AcromegalyKIRYAT GAT, Israel, Oct. 27, 2026 (GLOBE NEWSWIRE) -- OPKO Biologics Ltd., an OPKO Health company (NASDAQ: OPK), today announced that the first participant has been dosed in a first-in-human Phase 1/2a clinical trial of OPK-8801001, an investigational, long acting human growth hormone receptor antagonist being developed for the treatment of acromegaly.
18 days ago · benzinga.com
OPKO Health Sheds Diagnostics Businesses in Major Labcorp DealLabcorp Holdings Inc. (NYSE:LH) stock traded higher Thursday after the company agreed to acquire select assets of BioReference Health from OPKO Health Inc. (NASDAQ:OPK) in a deal worth up to $872 million.
1 month ago · zacks.com
Here's Why You Should Retain OPK Stock in Your Portfolio for NowOPKO Health eyes growth from RAYALDEE, partner revenues and a leaner BioReference, while pipeline and reimbursement risks remain key concerns.
1 month ago · zacks.com
OPK Stock Climbs 32.5% YTD: What's Driving the Rally in 2026?OPKO Health is gaining on pharmaceutical growth, a broad clinical pipeline, strategic partnerships and fresh non-dilutive financing.
2 months ago · marketbeat.com
OPKO Health Pivots to Therapeutics, Eyes Data-Rich 12 to 18 MonthsOPKO Health NASDAQ: OPK outlined a strategy to shift its business mix toward therapeutics while continuing to streamline its diagnostics operations, with management highlighting a pipeline of early-stage clinical programs, external collaborations and capital available to fund development.
2 months ago · globenewswire.com
OPKO Health to Participate in the Wells Fargo 21st Annual Healthcare ConferenceMIAMI, Sept. 08, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK), a fully-integrated healthcare company focused on delivering next-generation solutions for serious diseases across established global markets, today announced that Elias A.
2 months ago · zacks.com
Why Is OPKO Health (OPK) Down 9.7% Since Last Earnings Report?OPKO Health (OPK) reported earnings 30 days ago. What's next for the stock?
3 months ago · zacks.com
OPK Raises $125 Million Against Royalties: What Investors Should KnowOPKO Health secured $125 million in royalty-backed financing, adding non-dilutive capital while retaining long-term exposure to mazdutide growth in China.
3 months ago · zacks.com
Is OPK Worth Buying as Valuation Meets Improving Business Trends?OPKO Health pairs a discounted forward sales multiple with narrowing losses and partnership support, but early-stage clinical risk keeps the investment case balanced.
Analyst Summary
Add to Watchlist
Select watchlists to add or remove OPK